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Introduction 
The occurrence of complications in patients with cirrhosis such as jaundice, ascites, encephalopathy, 
infection, renal dysfunction or variceal bleeding requiring hospitalization alters the natural history of the 
disease with an increase in 5-year mortality as high as 40-50% (1). A significant proportion of these 
patients with acute decompensation require management in the intensive care unit (ICU) with organ 
support and have a high rate of in-hospital mortality. This category of patients with cirrhosis, acute 
decompensation and organ failure has been recently classified by a consensus conference as having acute 
on chronic liver failure  (ACLF) (2). Diagnosis of ACLF is made using the Chronic Liver Failure Organ 
Failure (CLIF) score (Table 1) and its prognosis is determined using the CLIF-ACLF score 
(www.clifconsortium.com, ACLF calculator). ACLF occurs in approximately 30% of hospitalized cirrhotic 
patients who present with a complication following an identified or unidentified precipitating even, is 
characterized by hepatic and / or extra-hepatic organ failures, and is associated with a 28-day mortality rate 
15 times higher than patients without ACLF (2, 3). In the US, each year, approximately 200,000 patients 
with cirrhosis are hospitalized of which approximately 10% require ICU care (3). The cost of providing 
health care to these patients amounts to about $13 billion per year (4).   
 ACLF is a newly recognized and complex condition in which the host response to injury and the 
type and number of organ failures all play important roles in determining the prognosis of the patient (2, 3). 
At present, the most effective management of patients with ACLF is unclear because of paucity of clinical 
trial data and lack of evidence-based guidance. The occurrence of ACLF increases the mortality risk, but 
the prognosis might be improved by optimal ICU management involving multiple disciplines, including 
hepatology, critical care, nephrology, infectious disease and transplant surgery.  It is with this in mind that a 
Consensus meeting, endorsed by the American Society of Transplantation (AST), American Society of 
Transplant Surgeons (ASTS) and European Association For the Study of the Liver (EASL), was organized 
whereby a group of invited experts in the field of liver transplantation reviewed the current knowledge of 
diagnostic approaches and treatment strategies that currently exist in the critical care management of 
patients with ACLF who are awaiting liver transplantation. The goal was to develop a consensus of 
opinions, based on best available evidence, on optimal practices and to articulate a research agenda to 




Prior to the conference, the organizing committee identified topics relevant to the management of patients 
with ACLF. A diverse international panel representing multiple relevant disciplines (nephrology, hepatology, 
transplant surgery, critical care / anesthesiology and infectious disease), from a variety of countries and 
scientific societies based on their expertise in this topic were assembled. Panelists were assigned to five 
person workgroups,with each work group addressing one key topic. Prior to the conference, each group 
identified a list of key questions, conducted a systematic literature search and generated a bibliography of 
key studies. We then conducted a 2½ day conference, whereby work groups assembled in breakout 
sessions, as well as in plenary sessions where their findings were presented, debated and refined. A series 
of summary statements was then developed during the breakout sessions and presented to the entire 
group, revising each statement as needed until a final version was agreed upon all members of the 
consensus meeting.  
 Each work group conducted literature searches related to their topic questions via MEDLINE, 
PubMed, and the bibliographies of all articles that met the search criteria. The majority of the work group 
resources were devoted to review of randomized trials, as these were deemed to be most likely to provide 
data to support level 1 recommendations with high quality evidence. The quality of the overall evidence and 
the strength of recommendations were graded using the Grading of Recommendations Assessment, 
Development and Evaluation system (Suppl. Table 1) (5). Recommendations were “Not Graded” if they 
were not based on systematic evidence and used to provide guidance where the topic did not allow 
adequate application of evidence. 
 
RENAL DYSFUNCTION 
Acute kidney injury (AKI) occurs in up to 50% of patients admitted with cirrhosis and represents one of the 
criteria that define ACLF (6-9). This increased risk of AKI is due to the combination of an impaired effective 
arterial blood volume secondary to arterial vasodilation, with increased intra-renal vasoconstriction and 
impaired renal autoregulation. Factors such as bacterial infections and gastrointestinal bleeding that further 
impair circulatory status and reduce renal perfusion can precipitate AKI (10-12). The development of AKI 
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not only increases the risk of mortality, but also reduces kidney function in the long-term following liver 
transplantation (13-17).  
Defining and Classifying Renal Dysfunction  
Recommendations 
1. We recommend that serum creatinine (Scr) values be interpreted with caution in cirrhotic 
patients especially those with ascites and fluid due to overestimation of values (1A). 
2. Diagnose and stage AKI in patients with liver disease guided by Kidney Disease Improving 
Global Outcomes (KDIGO) Scr and urine output (UO) criteria (Ungraded).  
3. Use a value of Scr obtained in the previous 3 months as baseline Scr. In patients with more than 
one value within the previous 3 months, the value closest to the hospital admission when the 
patient was stable can be used as the baseline. In patients without a baseline Scr value, the 
admission Scr should be used as the reference Scr (Ungraded).  
4. We do not recommend the use of estimated glomerular filtration rate (eGFR) equations for 
assessing renal function in patients with AKI (1D). 
Rationale. In the setting of cirrhosis, Scr tends to overestimate renal function due to decreased creatine 
production by the liver, protein calorie malnutrition, muscle wasting, reduced physical activity and enlarged 
volume of distribution in the setting of fluid overload (18). In addition, in the setting of AKI, Scr can lag by 
several hours to days despite a decrease in glomerular filtration rate (GFR) especially in the setting of fluid 
overload (19, 20). Serum cystatin C has not been shown to be superior to Scr in patients with cirrhosis (18, 
21, 22). Exogenous clearance markers such as inulin and iothalamate, are confounded by changes in 
volume of distribution, due to ascites and extracellular volume expansion. Among creatinine-based 
equations, it has been shown that the Modified Diet in Renal Disease 6 (MDRD-6) is the most accurate in 
cirrhosis (23-25). Equations based on cystatin C, with or without Scr (i.e., CKD-EPI creatinine-cystatin C 
equation) may be superior to creatinine-based equation (26, 27) however all equations tend to 
overestimate the true GFR and have been developed in study populations consisting of patients with 
chronic kidney disease (CKD) with stable Scr (28, 29).  
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 In 2010, an initiative supported by both the Acute Dialysis Quality Initiative (ADQI) and the 
International Club of Ascites (ICA) proposed adaptation of the Acute Kidney Injury Network (AKIN) criteria 
to define AKI in patients with cirrhosis which has been validated in several studies of hospitalized patients 
with cirrhosis (6-8, 30-35). These criteria were irrespective of whether the presumed cause of AKI was 
related to a functional or structural disorder. As such, type 1 hepatorenal syndrome (HRS) was categorized 
as a specific type of AKI,(6-8, 32-35) The current definitions of AKI depend on absolute or relative changes 
in Scr and urine output (Table 2) (30, 36-38). UO has been found to be a sensitive and early marker for AKI 
in ICU patients and to be associated with adverse outcomes (39-41). Although the severity of oliguria in the 
diagnosis of AKI has yet to be validated in patients with cirrhosis, worsening oliguria or development of 
anuria should be considered as AKI until proven otherwise, regardless of any rise in Scr (Fig. 1).  
 There remains some debate as to the most appropriate reference Scr to use to diagnose and stage 
AKI (38, 42-44). The ICA recently suggested that a baseline Scr result within the previous 3 months should 
be used as the reference, if available, or if no baseline exists, then the admission Scr can be used as the 
reference (38). Note that sometimes the reference Scr will only become apparent after renal function 
recovers. These patients have a better prognosis compared to those who do not recover renal function but 
still are at increased risk for CKD or death or over the ensuing months to years (38).  
Evaluation and Management of AKI 
Recommendations 
1. We recommend replacement of isotonic crystalloids in cases of volume loss due to diarrhea or 
over diuresis (1D), blood in cases of acute gastrointestinal hemorrhage (1D), and 20-25% 
albumin for infections (1A), suspected type-1 HRS (1A) or in cases where the cause of AKI is 
unclear (1D). 
2. We recommend to start treatment with vasoconstrictors and 25% albumin (1 gm/kg day 1 
followed by 20-40 gm /day) either when patients meet the ICA criteria of type-1 HRS (1A), or 
when there are evident signs of AKI progression as judged by a rapid increase in Scr when 
other causes of AKI have been ruled out (Fig. 2) (Ungraded). 
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3. In patients with type-1 HRS responding to vasoconstrictors and albumin with a decrease in Scr 
during the first days we recommend discontinuing treatment when Scr levels has reached or is 
close to baseline. If baseline Scr is unknown, we recommend discontinuing treatment when Scr 
does not decrease further after 3 days of treatment.   In non- responders, we recommend 
vasoconstrictors and albumin be stopped after a maximum of 7 days (1D).  
4. We recommend that in patients with evidence of worsening AKI, worsening fluid overload with > 
10% total body weight despite diuretic therapy or worsening acid-base status then renal 
replacement therapy (RRT) should be initiated (1D). 
Rationale. AKI should be suspected in the presence of increase Scr or decrease UO (Fig. 1). The 
diagnosis of type-1 HRS is particularly important since early initiation of treatment increases the likelihood 
of HRS resolution and may improve survival (45). An important step in the differential diagnosis of kidney 
dysfunction is to exclude parenchymal kidney disease as cause of AKI or AKI on a background of CKD 
(Suppl. Fig. 1).  
 Plasma volume expansion is an important step not only in the treatment but also in the differential 
diagnosis of the cause of AKI and the type of fluid needed for resuscitation should be tailored based on the 
etiology of AKI (Suppl. Fig. 1). If kidney function does not improve despite a trial of plasma expansion, 
type-1 HRS is the most likely diagnosis but still needs to be distinguished from acute tubular necrosis 
(ATN).  Several recent studies have shown that urine biomarkers, such as neutrophil gelatinase-associated 
lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1) in addition to urine 
microalbuminuria or fractional excretion of sodium may be helpful in not only diagnosing AKI earlier but 
also shedding light on the etiology of AKI (HRS vs ATN) and potentially help identify patients who are less 
likely to benefit from volume resuscitation and vasopressor therapy (32, 46-51).  
 
Type-1 HRS Treatment 
Patients in whom other causes of AKI have been ruled out should receive treatment for type-1 HRS with 
vasoconstrictors (Suppl. Table 2), which in conjunction with albumin, constitute the main therapy for type-1 
HRS (Figure 2) (45). Until now, vasoconstrictors have been typically initiated only when Scr reaches a 
threshold level of >2.5 mg/dL, however, type-1 HRS reversal and survival rates may improve with earlier 
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institution of vasoconstrictor therapy (52). Countries where terlipressin is not available, the combination of 
octreotide/midodrine can be initiated, and if there is no decline in Scr within a maximum of 3 days then the 
patient should be transferred to the ICU for a trial of norepinephrine(53, 54). All patients receiving 
vasoconstrictors should be monitored for ischemic and cardiovascular complications. Vasoconstrictors are 
not recommended in patients with pre-existing ischemic heart disease, cerebrovascular disease, peripheral 
arterial disease, hypertension or asthma.  
Renal Replacement Therapy (RRT) 
The initiation of RRT should be made on clinical grounds, including, volume overload, metabolic acidosis, 
hyperkalemia and hyponatremia not responding to medical management, and diuretic intolerance / 
resistance. RRT should be considered even in nonoliguric patients if the daily fluid balance cannot be 
maintained as even or negative (Suppl. Fig. 2). Continuous renal replacement therapy (CRRT) allows the 
option of adjusting dialysate and replacement solution flow rates or composition to allow for the slower 
correction of serum sodium in patients with hyponatremia and provides greater cardiovascular stability 
compared to standard intermittent hemodialysis (55, 56).  
 
CARDIO-PULMONARY DYSFUNCTION 
Circulatory changes in cirrhotic patients are characterized by increased cardiac output, peripheral 
vasodilatation, decreased systemic vascular resistance (SVR) and decreased oxygen extraction. 
Circulatory failure in cirrhotic patients with ACLF is distributive in nature and characterized by a greater 
decrease in arterial pressure associated with signs of impaired tissue perfusion. Marked splanchnic 
vasodilatation results in a state of effective hypovolemia with water and sodium retention (11). The 
activation of the renin-angiotensin system and other vasoconstriction systems results in renal 
vasoconstriction. This leads to impaired renal function, which can be further exacerbated by abdominal 
compartment syndrome in patients with tense ascites. Circulatory shock leads to further deterioration in 
liver function in patients with cirrhosis and contributes significantly to prognosis (57, 58). 
 
Goals of Resuscitation 
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Recommendations  
1. Achieve a mean arterial pressure that ensures organ perfusion (ungraded). We recommend 
individualizing the mean arterial pressure goal; in a cirrhotic patient in shock, a mean arterial 
pressure ≥ 60mmHg is usually appropriate (1D). 
2. We do not suggest use of a specific goal for blood lactate or venous oxygen saturation (Scv02) 
during fluid resuscitation (2C). 
3.  We recommend therapeutic paracentesis in patients with tense ascites (1A). 
4. We recommend careful attention and monitoring of patients, preferably with a pulmonary artery 
catheter (PAC) or echocardiography, during fluid resuscitation to avoid development of fluid 
overload (1D). 
Rationale. In septic shock, the first goal is to achieve a mean arterial pressure of 60 mmHg or more (59). 
No specific target for ventricular filling pressure, or volume, lactate, ScvO2, can be recommended (60). 
Trends are more informative than absolute values. A growing body of evidence suggests that over-zealous 
fluid administration with increases in tissue edema and total body water may lead to organ dysfunction and 
poor outcomes and thus, careful attention to fluid resuscitation is mandatory (61-65). Cirrhotic patients are 
particularly susceptible to development of extracellular edema, ascites and pulmonary edema with 
aggressive fluid administration. Increased edema formation and ascites can worsen intra-abdominal 
hypertension with resultant intra-abdominal compartment syndrome with decreases in respiratory 
compliance and impaired renal and cardiac function (66). Systematic measurement of intra-abdominal 
pressure is not recommended in patients with ascites however, in critically ill cirrhotic patients with tense 
ascites and clinical suspicion of abdominal hypertension, therapeutic paracentesis is recommended with 
albumin replacement as described below. 
 
Monitoring of Circulatory Status  
Recommendations 
1. We recommend placement of arterial catheters to guide therapy patients with circulatory shock 
receiving ongoing resuscitation (1D).  
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2. We recommend ensuring adequate venous access for fluids in patients with circulatory shock 
receiving ongoing resuscitation (1D); this will often require central venous access.  
3. We recommend the use of echocardiography as a first line option for initial evaluation of 
circulatory failure (1C). 
4. We recommend repeated measurements of blood lactate levels even though the interpretation 
may be complicated by the impaired clearance in cirrhosis (1A). 
5. We suggest the use of pulmonary artery catheter (PAC) for monitoring in patients with 
respiratory failure and/or persistent hemodynamic instability (2D). 
Rationale. In patients with circulatory shock, central venous and arterial lines should be routinely inserted 
(Fig. 3). Detailed hemodynamic monitoring may be needed, thus the first objective is to characterize the 
type of shock even though distributive shock is by far the most common pattern. Thereafter, secondary 
objectives are to assess myocardial function, to ensure venous return is adequate, vascular tone is 
restored, tissue oxygenation is optimized and to evaluate response to therapy (60). 
 The complex circulatory alterations in cirrhosis, especially patients with ACLF, complicate 
assessment of hemodynamics. Minimally invasive methods of assessing hemodynamic parameters such 
as stroke volume variation (SVV) and pulse pressure variation (PPV) have gained popularity in the ICU, 
however in patients who are spontaneously breathing, these methods have limited utility (Table 3) (67, 68). 
Such monitors have failed to demonstrate acceptable accuracy in cirrhotic patients undergoing liver 
transplantation, which further questions their role in the ICU (69). 
 Dynamic assessments of circulatory function including echocardiography are superior to static 
measures (70). Changes in central venous pressure (CVP) in response to volume challenge is more 
instructive than a single measurement and, when properly applied, passive leg raise may be used to 
assess volume responsiveness (68). Increased intra-abdominal pressure may result in increased CVP 
without improving cardiac preload.  In patients with suspected right ventricular dysfunction or in patients 
with pulmonary hypertension, a PAC may be indicated to guide resuscitation. PAC may also be useful in 
the management of complex cases in which fluid management is critical such as patients with respiratory 
failure or when clinical or radiologic findings do not allow differentiation of high pressure vs. low pressure 
pulmonary edema and pulmonary infection.  
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 Indirect markers of circulatory/tissue oxygenation status should be interpreted with caution in the 
context of cirrhosis; the levels in circulatory failure are higher in patients with cirrhosis as compared to 
patients without cirrhosis due to impaired liver function resulting in decreased lactate clearance (71). Thus, 
trends in serum lactate may be more informative than absolute values. A substantial part of fluid 
administered goes to the splanchnic circulation without restoring central effective volume. Worsening of 
tissue oxygen saturation (StO2), measured by near infrared spectroscopy, was recently shown to be 
associated with a poor prognosis in patients with cirrhosis (72). Whether StO2 as well as ScvO2 could be 
useful for monitoring is unknown.  
 
Choice of Fluid Therapy 
Recommendations 
1. We recommend use of crystalloid solutions as the initial fluid of choice in volume depleted 
patients (10-20 mL/kg) (1C).  
2. We recommend use of albumin (8g/L of ascites removed) following large volume paracentesis 
(>5L) (1B). 
3. We recommend patients with SBP should receive concentrated albumin (1.5 g/kg on day one 
followed by 1 g/kg on day 3) (1B). 
4. We suggest that in patients with suspected bacterial infection fluid resuscitation with 
crystalloids and a proportion of 4-5% albumin may be an option (2D). 
5. We recommend against the use of hydroxyethyl starch (HES) (1B).  
Rationale. In volume depleted patients with distributive shock, crystalloids (normal 0.9% saline) are 
recommended at an initial dose of 10-20 mL/kg (73). However, balanced salt solutions (such as 
PlasmaLyte®) may be preferred to normal saline in patients with hyperchloremic acidosis (74) and in 
patients with relative hyperchloremia (e.g. those with “normal” chloride in the setting of low serum sodium).  
In patients with evidence of fluid overload (tense ascites, generalized edema, CVP > 12 mmHg) fluid 
administration should be discontinued. 
 There are theoretical benefits to the use of albumin in patients with cirrhosis beyond simple volume 
expansion based on its numerous biological properties (75). Patients with cirrhosis should receive albumin 
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in 3 specific situations: spontaneous bacterial peritonitis (SBP), large volume paracentesis and type-1 HRS 
(76). Randomized controlled trial haa shown that in patients with SBP, antibiotics plus albumin are superior 
to antibiotics alone in prevention of the occurrence of type-1 HRS (45, 77). Albumin is also recommended 
in patients with large volume paracentesis as it is superior to crystalloids in preventing post-paracentesis 
circulatory dysfunction (78-80). In cirrhotic patients with infections other than SBP, two controlled trials 
showed that the administration of albumin in combination with antibiotics did not improve survival, however 
the incidence of AKI was significantly lower with albumin (81, 82).  
 HES solutions may have harmful effects in patients with sepsis and should be avoided due to 
potential nephrotoxicity (83, 84).  
 
Pharmacological Management of Persistent Shock 
Recommendations 
1. We recommend the use of norepinephrine as the first line vasopressor agent (1A). Vasopressin 
or terlipressin are appropriate second line agents for persistent hypotension (1B). 
2. A trial of hydrocortisone 200-300 mg/day in divided doses in patients with refractory 
hypotension should be started and stopped following improvement in hemodynamics (1C). 
Rationale. Norepinephrine is the first line agent as this agent is associated with fewer adverse events (85). 
Vasopressin or terlipressin may be used as second line agents and have demonstrated improvements in 
hemodynamics and norepinephrine sparing in patients with cirrhosis (53, 86-89). 
 Adrenal insufficiency (AI) is common in critically ill patients with cirrhosis, however, it could also be 
a feature of liver disease per se and not simply related to critical illness (90-93). So far, there has not been 
a consensus about the appropriate method for the precise AI diagnosis in patients with cirrhosis. The use 
of corticosteroids in critically ill patients with cirrhosis has been associated with a significant reduction in 
vasopressor doses and higher rate of shock reversal (94-96). Survival benefit however, was demonstrated 
in some (91, 95) but not all studies (94, 96). In patients with increasing vasopressor requirements 
hydrocortisone 200-300 mg/day in divided doses should be administered (93, 97).  
 
PREVENTION AND MANAGEMENT OF INFECTIONS 
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Patients with advanced cirrhosis are at increased risk for bacterial and fungal infections because of several 
key factors: 1) dysbiosis (i.e., alterations of the gut microbiome 2) small intestinal bacterial overgrowth, 3) 
increased bacterial translocation 4) immunocompromised state, and 5) increased rate of resistant organism 
colonization (2, 10, 98-103). Once infection occurs and leads to ACLF (10, 23), the compensatory anti-
inflammatory response increases the risk for subsequent infections with further worsening in prognosis (3, 
104). Following an episode of infection, the decision to reactivate a patient for transplant should balance 
the benefit of transplant with the risk of post-operative infectious complications (Table 4).  
 
Antibiotic Prophylaxis 
Following Gastrointestinal Bleeding (GIB) 
Recommendations 
1. We recommend immediate antibiotic prophylaxis for 7 days following GIB (1A), although the 
absolute benefit and required duration are not clear in patients with compensated cirrhosis 
after rapid control of bleeding (2D). 
2. We recommend IV ceftriaxone for GIB prophylaxis in patients with severely decompensated 
cirrhosis with active bleeding who are on a quinolone at admission or have a history of 
quinolone resistant infection. Quinolones are recommended in the remaining patients (1A). 
Rationale. Following an episode of GIB, antibiotic prophylaxis is currently recommended (105) as it 
decreases the risk of infection, rebleeding, infection related and all-cause mortality (106, 107). Most studies 
evaluated 7 days of antibiotic therapy, but in patients with rapid control of bleeding and less severe liver 
disease, shorter course therapy may be acceptable. Controversy remains regarding the necessity of 
antibiotic prophylaxis in compensated cirrhosis. When administering antibiotic prophylaxis after GIB, the 
majority of studies utilized norfloxacin 400 mg orally twice daily or ceftriaxone 1 gm intravenously daily 
(106, 108). Oral ciprofloxacin has limited data on its efficacy, but would be the preferred alternative where 
norfloxacin is unavailable. In patients with more advanced liver disease with at least 2 of the following: 
ascites, hepatic encephalopathy, jaundice, or severe malnutrition, superior results were achieved with IV 
ceftriaxone (95, 109). IV ceftriaxone should also be considered in patients with active GIB, on a quinolone 
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at admission, with a history of a quinolone resistant infection, or who live in regions with a high prevalence 
(≥20%) of quinolone resistance.  
 
Spontaneous Bacterial Peritonitis (SBP) 
Recommendations 
1. We recommend primary SBP prophylaxis only in patients with low protein ascites (<1.5 g/dL) 
and renal and/or liver impairment and secondary SBP prophylaxis in all patients (1A). 
2. We recommend SBP prophylaxis with norfloxacin 400 mg daily. Ciprofloxacin 500 mg or 
trimethoprim/sulfamethoxazole (TMP-SMX) 160/800mg daily can be used if norfloxacin is 
unavailable (1A). 
3. We do not recommend weekly quinolones (1C) nor probiotics alone (2C) or in combination with 
antibiotics (2D) for SBP prophylaxis. 
4. Resistant infections can occur in patients on SBP prophylaxis, after which the ideal antibiotic 
prophylactic strategy is not known (2D).  
Rationale. Current guidelines only recommend primary SBP prophylaxis in highly selected patients: ascitic 
fluid total protein <1.5 g/dL and renal impairment (Scr ≥1.2 mg/dL, BUN ≥ 25 mg/dL or serum Na ≤130 
mEq/L) or Child Pugh Turcotte ≥9 with serum bilirubin ≥3 mg/dL. A meta-analysis confirmed improved 
outcomes in patients receiving primary prophylaxis with a decrease in serious infections, SBP and mortality 
(110), however, development of resistant infections is the major concern with this approach.  
 When choosing an antibiotic for prophylaxis, norfloxacin 400 mg/day is the best studied (111-113). 
In areas where norfloxacin is unavailable ciprofloxacin 500 mg or TMP-SMX 160/800 daily can be used 
(114). Weekly quinolone therapy is not recommended because of inferior efficacy and increased risk of 
resistance. Limited data has not demonstrated reduced risk of SBP with probiotic administration alone or in 
combination with antibiotics (115). Since no clinical studies have been performed, SBP prophylaxis in 
patients with prior antibiotic-resistant bacteria is a critical area of research required. 
 
Other Antibiotic Prophylactic Strategies 
Recommendations 
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1. We suggest universal decontamination with intranasal mupirocin and chlorhexidine baths of 
ICU patients as part of a hospital wide plan to decrease bloodstream infections (2B). 
2. We recommend antibiotic-impregnated catheters only when a comprehensive strategy to 
reduce the rate of central line associated blood stream infections has failed and the line will 
remain >5 days (1A). 
Rationale. Universal decontamination of patients, using twice daily intranasal mupirocin and daily 
chlorhexidine baths, is associated with a statistically significant decrease in bloodstream infections (116). 
While studies of this intervention included few cirrhotic patients, the results likely apply to this population.  
 The best approach to prevent catheter-associated infections is to avoid unnecessary 
catheterizations and to remove them when no longer necessary (117). Foley catheters should only be 
inserted when clinically indicated to decrease the risk of bacteriuria (5-10% / day ≥2 days after insertion) 
and infection. In patients with long-term indwelling catheters antibiotic coated catheters could be 
considered, without definitive evidence that they reduce infections. However, use of antibiotic-impregnated 
catheters in those expected to remain >5 days could be recommended only if a comprehensive strategy to 
reduce the rate of central line associated blood stream infections has been implemented without success. 
Replacement of central lines in the absence of infection is not recommended (118).  
 
Treatment of Infectious Complications 
Recommendation 
1. We recommend that antibiotic therapy should be tailored to the specific pathogen once 
identified. If a pathogen is not identified, ongoing therapy and evaluation should be determined 
by the patient’s clinical course (1B). 
Rationale. Discussing specific infection treatment algorithms is outside the scope of this manuscript (119); 
however, since severe sepsis is a common complication of cirrhotic patients with acute decompensation 
(120), important diagnostic and management strategies are highlighted in Figure 4. When working up a 
patient with suspected infection, inflammatory biomarkers such as serum C-reactive protein (CRP) or 
procalcitonin can be useful; one is not superior to the other (Suppl. Table 3) (121). Serum CRP levels 
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increase to a lesser extent during infection in patients with more advanced liver disease, but can still be 
used to identify infection and improvement.  
 Once severe sepsis is suspected, a thorough evaluation should be promptly followed by antibiotic 
administration, since each hour delay impairs outcome (122). In patients with clinical improvement within 
48-72 hours and a known pathogen, immediate tailoring of antibiotics is recommended; matrix-assisted 
laser desorption/ionization time of flight (MALDI-TOF) testing (123) in countries where it is commercially 
available (currently unavailable in the US) may facilitate de-escalation. In patients without clinical 




1. We do not recommend treatment in patients with asymptomatic candiduria (1D).   
2. We recommend antifungal therapy in intubated patients with yeast in sputum or bronchial 
lavages (BAL) with an additional positive fungal culture at another sterile site (1B). 
3. We recommend antifungal therapy in ICU patients without clinical improvement after 48 hours 
and in high prevalence (>5%) regions or with risk factors for development of invasive fungal 
infections (1D). 
Rationale. In addition to having an increased susceptibility to bacterial infections, patients with advanced 
liver disease are at higher risk for fungal infections likely due to significant immunologic impairment, 
increased intestinal permeability, frequent use of corticosteroids, malnutrition and performance of invasive 
procedures (125, 126). 
 In patients with multifocal candida colonization with clinical risk factors for infection but who remain 
in stable condition, preemptive therapy is not indicated. BAL candida isolation generally indicates 
colonization but not infection(127). Initial therapy for candiduria should include Foley catheter removal or 
exchange. Although amphotericin bladder washes are generally not recommended, it may be useful for 
treatment of patients with refractory cystitis due to fluconazole-resistant candida species such as candida 
glabrata and krusei (128, 129).  Antifungal therapy should be considered in patients with two positive 
cultures from different sites, isoltated positive blood culture and in septic patients without improvement for 
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48 hours (Fig. 4)(129).. As recommended in the general population, critically ill cirrhotic patients should 
receive echinocandins as first line therapy (129, 130). Azoles should be used during de-escalation after 
susceptibility has been confirmed. 
 Antifungal prophylaxis may be used in ICU patients without clinical improvement in high prevalence 
areas or in those with multiple risk factors for infection (corticosteroid use, prolonged microbial use, central 
venous catheter, total parenteral nutrition, high APACHE score, renal replacement therapy, or 
malnutrition)(131). 
 
ALTERATIONS IN HEMOSTASIS  
Patients with acute decompensation of cirrhosis, especially those with ACLF, are in a fragile continuum 
between ineffective hemostasis and excessive coagulation. Alterations in primary hemostasis, secondary 
hemostasis and fibrinolysis results in disturbance of this balance which leads to either bleeding or 
thrombotic episodes (Fig. 5) (132-135). Pathophysiological conditions of ACLF that may further disturb 
cirrhotic hemostatic imbalance include hemodynamic instability (133, 136), endothelial dysfunction (133), 
development of endogenous heparin-like substances due to infection (133, 136) and renal dysfunction 
(137). 
 
Clinical and Laboratory Tests to Assess the Risk of Bleeding and Thrombosis  
Recommendations 
1. INR does not provide an adequate assessment of hemostasis in cirrhosis (2B). 
2. We recommend against routine prophylactic use of fresh frozen plasma (FFP)(1B). 
3. We suggest maintaining platelet counts above 50 x 109/L in the presence of active bleeding (2C). 
4. We recommend a hemoglobin transfusion trigger of 7 mg/dl (1A). Erythropoietin 
supplementation does not have a role in the absence of chronic kidney disease (1B). 
5. Viscoelastic testing should be considered during liver transplantation and other major surgery 
(cardiac, major trauma). Its role in the ICU setting or prior to invasive procedures requires 
further evaluation (2C). 
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6. We suggest anticoagulation with unfractionated/low molecular weight heparin in patients with 
occlusive portal vein thrombosis in the absence of bleeding risk factors (2C). 
Rationale 
Internationalized Ratio (INR) /Prothrombin Time (PT) 
The INR is based on the PT which itself depends on the level of procoagulant factors I, II, V, VII, and X. It 
does not account for deficiencies of the anti-coagulation system (especially low protein C), which may 
result in a hypercoagulable state not reflected in prolongation of the INR. Together with elevated 
endothelial-derived factor VIII, the low protein C causes thrombin generation to be normal or even high in 
cirrhosis (132). Inter-laboratory variation in the INR in cirrhosis (due to absence of normalization of 
thromboplastins to a standard based on liver disease) makes INR ‘cut-off’ values of little value (138). 
Furthermore, thrombin production does not improve when normal plasma is transfused despite 
improvements in INR (139). Standard doses of FFP rarely correct coagulopathy of cirrhosis (133, 140), and 
can be harmful due to increases in portal pressure during variceal bleeding (141).  
 
Platelet Count  
Despite thrombocytopenia in cirrhosis, platelet adhesion in vitro is preserved by increased levels of von 
Willebrand factor (decreased ADAMTS13) (133). Using thrombin (factor II) production as a surrogate for 
clot formation, platelet counts exceeding 50x109/L are associated with adequate thrombin formation, 
making this a practical clinical target in the setting of active bleeding or as prophylaxis prior to procedures 
(133, 142). However, prophylactic transfusion of a single adult platelet unit is of marginal benefit in 
increasing the platelet count to target levels (143). Despite laboratory data, there is no clinical evidence of a 
definitive threshold that correlates with increase bleeding risk during surgery (i.e. liver transplant) or 
invasive procedures (including liver biopsy).  
 
Hemoglobin Targets  
A recent study demonstrated that a restrictive hemoglobin transfusion target (7 mg/dl) was not inferior to a 
liberal strategy (9 mg/dl), and may have benefit in patients with Child Pugh A and B (144). Endogenous 
erythropoetin levels are elevated in cirrhotic patients and correlate with the severity of portal hypertension 
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(145). Exogenous erythropoetin stimulates increased thrombopoiesis and platelet reactivity possibly 
exacerbating the risk of thrombosis (146).  
 
Viscoelastic Tests of Whole Blood Coagulation 
Viscoelastic tests, which include thromboelastography (TEG), thromboelastometry (ROTEM) and 
sonorheometry, offer a means of assessing the activity of pro- and anti-coagulant pathways as well as 
providing a means of recognizing hyperfibrinolysis or premature clot dissolution (147). The tests are in vitro 
assays and do not account for the in vivo contributions of the endothelium and blood flow. Assessment of 
clotting can be performed in 10-20 minutes; however, assessment of fibrinolysis takes 30-60 minutes (148). 
Viscoelastic testing suggests that hypercoagulability is more prevalent in patients with cholestatic liver 
disease, acute liver failure and nonalcoholic steatohepatitis (149, 150). The management of patients with 
hypercoagulability on viscoelastic testing is not clear; however, pro-coagulants and antifibrinolytics should 
be used cautiously in these patients. 
 
Venous Thromboembolic Disease and Anticoagulant Therapy 
Increased risks of venous thromboembolic disease (0.5-2% absolute risks) have been demonstrated in 
cirrhotic patients, especially in those patients with hypoalbuminemia (151, 152). Rates of portal vein 
thrombosis have been reported as approximately 8% per year with morbidity and mortality at one year 
impacted by prophylactic anticoagulation (153, 154). Anticoagulation demonstrates the most utility in 
patients with more extensive portal vein and mesenteric thrombosis in the absence of other risk factors for 
bleeding (153, 155). Low molecular weight heparin does not appear to increase risk of variceal bleeding 
(156) and is likely the safest choice. However it should be considered that it has an increased clinical effect 
despite decreased antithrombin III levels in cirrhotic patients (157).  
 
Bleeding Risks for Minimally Invasive and Surgical Procedures  
Recommendations 
1. We suggest transfusion to a platelet count above 50x109/L prior to minimally invasive procedures 
(2C). 
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2. During surgical procedures, viscoelastic testing should be considered to guide coagulation 
management (2C). 
3. We suggest maintaining fibrinogen levels > 1.5 g/L in patients with significant bleeding or 
during invasive / surgical procedures (2C). 
Rationale. Bleeding rates after minimally invasive procedures in cirrhotic patients have been demonstrated 
to be low for paracentesis (0-3.3%) and thoracentesis (2%) (158). Bleeding does not appear to correlate 
with platelet count or INR. Reported incidence of major bleeding complications after liver biopsy was 
between 0.22 and 0.58% with a 0.1% mortality. Bleeding rates were higher in patients with advanced 
hepatic fibrosis and platelet count ≤60x109/L (159, 160). Transjugular liver biopsy has been shown to be 
relatively safe even in those patients with decreased platelet count or prolonged INR (161). Risk of 
bleeding after liver surgery has been shown to correlate with surgical and hemostatic techniques rather 
than coagulation parameters (162). Although the optimal fibrinogen level is uncertain (normal 2-4.5 g/L), in 
bleeding/surgical patients, fibrinogen levels of > 1 g/L are recommended (163, 164). More recent guidelines 
suggest higher levels (>1.5-2.0 g/L) are beneficial in major trauma with significant bleeding, a 
recommendation which aligns with in vitro levels required for optimal clot formation time on viscoelastic 
testing (165, 166). The routine use of viscoelastic testing during liver transplantation appears well 
established as a means to determine global coagulation status (167). 
 
Role of Novel Coagulation Agents/Complexes  
Recommendations 
1. We suggest prothrombin complex concentrates before invasive procedures preferably guided 
by viscoelastic testing (2D). 
2. We recommend against routine use of thrombopoeitin receptor agonists (1B). 
3. We suggest antifibrinolytic therapy (tranexamic acid or ε -aminocaproic acid) use in 
decompensated cirrhosis with bleeding when hyperfibrinolysis is suspected or proven. 




Prothrombin complex concentrates (PCC) are available as 3-factor (FII, IX, X) and 4-factor products (same 
factors plus FVII). Some contain endogenous anticoagulants (protein C, protein S, antithrombin III) with or 
without heparin in an attempt to lessen the thrombotic risk (168). Thrombotic complications in ACLF 
patients may be reduced by limiting repeat dosing of PCCs. Factor II and X have long half-lives (60 and 30 
hrs. respectively) and may accumulate during repeated administration. Thromboelastometry-guided PCC 
administration, when compared to FFP transfusion for massive trauma, resulted in a higher likelihood of 
avoidance of red blood cell and platelet transfusion (169).  
 
Thrombopoetin Receptor Agonists 
In trials, the oral thrombopoetin receptor agonist eltrombopag increased platelet count in thrombocytopenic 
HCV patients, improving tolerance of anti-HCV therapy (170). However, in the ELEVATE study, 6 
eltrombopag-treated patients developed portal vein thrombosis (171). Nplate (romiplostim), administered to 
thrombocytopenic HCV patients prior to procedures, improved platelet counts and facilitated interventions 
without experiencing procedural bleeding or thrombosis (172). However, other reports suggest increased 
thrombotic risk, particularly in patients with platelet counts over 200 x 109/L (173). 
 
Antifibrinolytics 
Aprotinin, the most extensively studied antifibrinolytic, is efficacious for reducing transfusion requirements 
during transplant (174, 175). Aprotinin has been controversial and was withdrawn from the market in the 
wake of a cardiac surgery trial showing increased mortality (176). In an uncontrolled study, ε-aminocaproic 
acid (Amicar) was deemed effective and safe for treatment of hyperfibrinolysis in patients with cirrhosis 
(177). Viscoelastic testing during antifibrinolytic therapy is recommended. 
 
NEUROLOGIC DYSFUNCTION 
Mechanisms behind neurological dysfunction, mostly which is caused by hepatic encephalopathy (HE) in 
hospitalized cirrhotic patients, are varied and are often overlapping with concurrent or precipitating illnesses 
such as infections and electrolyte abnormalities (178). Studies of the brain have demonstrated alterations 
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in ammonia metabolism, brain and systemic inflammation, and changes in cerebral blood flow and 
oxygenation (179). 
 
Diagnosis of HE  
Recommendations 
1. We suggest brain imaging only be used for overt HE at its first occurrence if: a) the onset of the 
symptoms is abrupt and severe, b) there are focal neurological signs, or c) there is limited or no 
response to treatment of the precipitating factor and/or to ammonia lowering strategies. 
Electroencephalogram (EEG) can be used to exclude other causes of altered mental status (2D). 
2. Measurement of fasting ammonia levels can be informative only if it is normal in a confused, 
disorientated or comatose patient with cirrhosis (2D). 
Rationale. The differential diagnosis of HE is vast and should be rigorously investigated (Table 5) (10, 23, 
179, 180). EEG changes, are non-specific and of limited value in the diagnosis of HE, nevertheless they 
can assess HE severity and exclude other causes of altered mental status (181). The risk of intra-cerebral 
hemorrhage is increased in cirrhotic patients and thus, brain imaging could be useful to exclude other 
causes of altered mental status (182). 
 To differentiate HE from other conditions, fasting ammonia levels can be relevant since, in a 
confused, disorientated or comatose cirrhotic patient, the finding of normal plasma ammonia levels 
suggests an alternative cause of neuropsychiatric abnormalities (179). Nevertheless, one should be 
warned against the use of high ammonia levels alone for purpose of diagnosing of HE since false positive 




1. We recommend the use of West-Haven criteria (WHC) for clinical use provided it is refined 
using tools such as clinical HE staging scale (CHESS), HE scoring algorithm (HESA) or 
modified orientation log (MO-log) (1C).  
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2. We recommend the Glasgow coma scale (GCS) for clinical use and to guide need for airway 
protection (1B). 
3. We suggest head Imaging studies and EEG only to exclude other causes especially when there 
is lack of response to therapy (2D). 
Rationale. Grading of mental status is important to assess and document the progression of disease and 
the impact of treatment. Currently there are no available tools that reliably distinguish HE from other 
etiologies of metabolic encephalopathy. Although simplicity and familiarity favor usage of the WHC to grade 
and monitor HE for clinical purposes, these criteria are not reliable in the earlier stages and therefore other 
questionnaires have been studied to refine the assessment (Suppl. Table 4) (183-187). Use of HESA, MO-
log or CHESS may be considered for clinical research or practice where the outcome of interest is the 
presence, absence or change in HE. The GCS is a simple and widely utilized tool for characterizing 
neurologic dysfunction after traumatic brain injury (188) that has been applied to metabolic encephalopathy 
(189). Its greatest utility is defining the threshold (<8) below which airway protection may be required. Serial 
brain imaging and EEG assessments beyond exclusion of other causes and investigation of lack of 
improvement have not been shown to be clinically useful. 
 
Therapy for HE 
Recommendations 
1. We recommend the use of lactulose as the initial therapy for HE with close monitoring of 
electrolytes and the development of ileus (1C).  
2. We do not recommend the use of neomycin, LOLA, IV albumin or other laxatives for the 
treatment of HE (1D). 
3. We suggest albumin dialysis in patients with encephalopathy that is refractory to medical 
therapy (2C). 
4. We recommend HE-specific therapies such as lactulose and rifaximin to be started to prevent 
recurrent episodes (1A). 
 
	 25 
Rationale. In patients with altered mental status, specific therapies for HE is often initiated along with 
treatment of the precipitating factors such as GI bleeding, electrolyte disorders, renal dysfunction, 
medications (Fig. 6). Recurrence of HE has emerged as one of the leading causes for re-admission in 
cirrhotic patients (190). Lactulose, rifaximin and the probiotic VSL#3 have been shown to prevent HE 
recurrence (191-193). 
Lactulose: The use of lactulose in hospitalized cirrhotic patients is hampered by trials with low sample sizes 
(194). Nevertheless, it continues to be used as first-line therapy for HE. The specific mode of administration 
is critical to prevent aspiration, especially in advanced stages of HE and over-administration can result in 
HE recurrence (195). The oral dose is 20 ml per hour till at least one bowel movement and then reduced to 
20-30 ml BID to TID titrated to 2-3 soft bowel movements per day (179). Following an episode of acute 
variceal bleeding, studies have shown that mental status significantly improved after lactulose compared to 
no treatment and there was equivalent improvement with lactulose compared to rifaximin (196, 197). 
Studies comparing simple laxatives (polyethylene glycol (PEG) orally, saline enemas) to acidifying enemas 
or laxatives such as lactulose, lactitol and lactose, have shown a significant benefit of the “acidifying” 
enemas on mental status (198). In contrast a recent study showed superiority of PEG compared to 
lactulose in mental status improvement (199). Given the small number of patients in both studies further 
large-scale studies are needed to find out the differences between laxatives and potential acidifying agents. 
Rifaximin: Current standard of care does not include rifaximin in the treatment of an HE episode but does 
not call for discontinuation if patient was already taking it as an outpatient (200). Mas et al. demonstrated 
equivalent global recovery, (despite greater improvement in ammonia and EEG in rifaximin) with rifaximin 
when it was directly compared to lactitol in patients with an episode of HE (201).This was followed by a 
study in which combined rifaximin and lactulose showed superior efficacy over lactulose alone (202). These 
two studies used different comparators and need to be replicated before routine rifaximin use can be 
recommended. 
Albumin and Albumin Dialysis: Although in one controlled trial, treatment with albumin improved HE in 
patients with diuretic-related HE (203), in a randomized control trial, the primary endpoint of HE resolution 
was not reached but there was a survival benefit (179). Several studies have found a significant 
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improvement in HE using albumin dialysis compared to standard medical therapy (204-207). However, only 
a few small studies have shown overall survival benefit (208-210). While the role of these therapies is being 
debated, their use as a bridge to liver transplant by providing temporary support of organ failure (liver, 
kidney and brain) is a potentially important goal in this situation. 
Neomycin: Neomycin was the first drug approved for HE treatment in the US and was the standard to 
which lactulose was compared. Several underpowered studies with lactulose and neomycin demonstrated 
similar outcomes regarding mental status (179). However due to several adverse effects (nephro/oto-
toxicity), the use of neomycin has fallen out of favor. 
L-ornithine L-aspartate (LOLA): IV LOLA has been shown to improve mental status in one high-quality 
German trial, which has been replicated at least once in other countries. However, this drug is not available 
in the United States (211). 
 
Intubation and Sedation 
Recommendations 
1. We recommend intubation in patients with GCS <8 (1D). 
2. We recommend sedation with short acting agents and avoidance of benzodiazepines (1D). 
 
Rationale. All patients with HE WHC grade 3 or 4 and GCS <8 should be considered for intubation for 
airway protection (180). Short acting drugs such as propofol or dexmedetomidine should be used, with 
caution paid to hemodynamic side effects (212). Dexmedetomidine is associated with preservation of 
cognitive function (213) and reduced duration of mechanical ventilation in ICU patients (214) and may be 
used for the management of alcohol withdrawal which may allow decreased benzodiazepine administration 
(215). Both dexmedetomidine and propofol are associated with similar hemodynamic side effects (216). 
 
Conclusion 
ACLF is a recently recognized syndrome associated with multi organ/system failure(s) (liver, kidney, brain, 
coagulation, circulation and/or respiration) and with an extremely poor survival. These patients often 
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require ICU care. The optimum treatment of patients with ACLF is evolving and further programmatic 
clinical research are essential to determine the mechanisms of organ failure in ACLF and to help develop 




The authors wish to acknowledge the University of Southern California Keck School of Medicine for 





1. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, et al. Compensated 
cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128. 
2. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, et al. Bacterial 
infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 
2014;60:1310-1324. 
3. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, et al. Acute-on 
chronic liver failure. J Hepatol 2012;57:1336-1348. 
4. Olson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia-Tsao G, Kamath PS. Intensive care 
of the patient with cirrhosis. Hepatology 2011;54:1864-1872. 
5. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, et al. Grading quality of 
evidence and strength of recommendations. BMJ 2004;328:1490. 
6. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, Morando F, et al. Evaluation of the 
Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 
2013;59:482-489. 
7. Wong F, O'Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, et al. New 
consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis 
and infection. Gastroenterology 2013;145:1280-1288  
8. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut 2013;62:131-
137. 
9. Barreto R, Fagundes C, Guevara M, Sola E, Pereira G, Rodriguez E, Graupera I, et al. Type-1 
hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, 
and survival. Hepatology 2014;59:1505-1513. 
10. Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a 
vasomotor nephropathy. Kidney Int 2015;87:509-515. 
11. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290. 
	 29 
12. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, Jalan R. 
Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in 
cirrhosis. Gastroenterology 2008;134:111-119. 
13. Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R. Impact of the 
etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus 
hepatorenal syndrome. Liver Transpl 2012;18:539-548. 
14. Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, Bloom RD, et al. 
Transplantation: impact of pretransplant renal insufficiency. Liver Transpl 2008;14:665-671. 
15. Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, et al. 
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine 
elevation. Liver Transpl 2005;11:1048-1055. 
16. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of 
preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD 
lead us? Am J Transplant 2006;6:2651-2659. 
17. Hilmi IA, Damian D, Al-Khafaji A, Planinsic R, Boucek C, Sakai T, Chang CC, et al. Acute kidney 
injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft 
outcomes. Br J Anaesth 2015. 
18. Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in 
patients with cirrhosis--potential inequity for access to treatment of hepatorenal failure and liver 
transplantation. Nephrol Dial Transplant 2011;26:2735-2742. 
19. Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. 
Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care 
2010;14:R82. 
20. Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, Wright P, et al. 
Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute 
kidney injury and associated outcomes. Crit Care Med 2011;39:2665-2671. 
	 30 
21. Xirouchakis E, Marelli L, Cholongitas E, Manousou P, Calvaruso V, Pleguezuelo M, Guerrini GP, et 
al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA 
clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2011;6:84-92. 
22. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a 
marker of renal function in patients with cirrhosis of the liver. Gut 2002;50:106-110. 
23. Francoz C, Nadim MK, Baron A, Prie D, Antoine C, Belghiti J, Valla D, et al. Glomerular filtration 
rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current 
recommendations. Hepatology 2014;59:1514-1521. 
24. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients 
with cirrhosis. J Hepatol 2010;52:605-613. 
25. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular 
filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver 
Transpl 2004;10:301-309. 
26. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of 
chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney 
function in cirrhosis. Hepatology 2014;59:1532-1542. 
27. De Souza V, Hadj-Aissa A, Dolomanova O, Rabilloud M, Rognant N, Lemoine S, Radenne S, et al. 
Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver 
transplantation with cirrhosis. Hepatology 2014;59:1522-1531. 
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal 
Disease Study Group. Ann Intern Med 1999;130:461-470. 
29. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, et al. A 
new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612. 
30. Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, et al. Hepatorenal 
syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) 
Group. Crit Care 2012;16:R23. 
	 31 
31. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, et al. Working Party 
proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011;60:702-
709. 
32. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, et al. Association of 
AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013;57:753-762. 
33. de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, Moraes 
Coelho HS, et al. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients 
with ascites. J Clin Gastroenterol 2012;46:e21-26. 
34. Fagundes C, Barreto R, Guevara M, Garcia E, Sola E, Rodriguez E, Graupera I, et al. A modified 
acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in 
cirrhosis. J Hepatol 2013;59:474-481. 
35. Wong F, O'Leary JG, Reddy KR, Kamath PS, Garcia-Tsao G, Maliakkal B, Subramanian R, et al. A 
cut-off serum creatinine value of 1.5mg/dl for AKI - To be or not to be. J Hepatol 2015;62:741-743. 
36. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury 
Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. 
37. KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group 
KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int 2012;Suppl.:1-138. 
38. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, et al. Diagnosis and 
management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the 
International Club of Ascites. J Hepatol 2015;62:968-974. 
39. Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. Classifying AKI by Urine 
Output versus Serum Creatinine Level. J Am Soc Nephrol 2015. 
40. Macedo E, Malhotra R, Bouchard J, Wynn SK, Mehta RL. Oliguria is an early predictor of higher 
mortality in critically ill patients. Kidney Int 2011;80:760-767. 
41. Macedo E, Malhotra R, Claure-Del Granado R, Fedullo P, Mehta RL. Defining urine output criterion 
for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2011;26:509-515. 
	 32 
42. Siew ED, Matheny ME, Ikizler TA, Lewis JB, Miller RA, Waitman LR, Go AS, et al. Commonly used 
surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney 
Int 2010;77:536-542. 
43. Zavada J, Hoste E, Cartin-Ceba R, Calzavacca P, Gajic O, Clermont G, Bellomo R, et al. A 
comparison of three methods to estimate baseline creatinine for RIFLE classification. Nephrol Dial 
Transplant 2010;25:3911-3918. 
44. Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to 
detail? Kidney Int 2015;87:46-61. 
45. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on 
vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-584. 
46. Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, Ansari N, 
et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol 
2014;9:1857-1867. 
47. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, Ansari N, et al. 
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 
2014;60:622-632. 
48. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, et al. 
Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in 
cirrhosis. Dig Dis Sci 2012;57:2362-2370. 
49. Fagundes C, Pepin MN, Guevara M, Barreto R, Casals G, Sola E, Pereira G, et al. Urinary 
neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney 
function in cirrhosis. J Hepatol 2012;57:267-273. 
50. Barreto R, Elia C, Sola E, Moreira R, Ariza X, Rodriguez E, Graupera I, et al. Urinary neutrophil 
gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial 
infections. J Hepatol 2014;61:35-42. 
51. Ariza X, Sola E, Elia C, Barreto R, Moreira R, Morales-Ruiz M, Graupera I, et al. Analysis of a 
urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One 2015;10:e0128145. 
	 33 
52. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin 
improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 
2007;46:1863-1871. 
53. Albanese J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic 
shock: a prospective, randomized study. Crit Care Med 2005;33:1897-1902. 
54. Nassar Junior AP, Farias AQ, LA DA, Carrilho FJ, Malbouisson LM. Terlipressin versus 
norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS 
One 2014;9:e107466. 
55. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined 
acute renal and fulminant hepatic failure. Kidney Int Suppl 1993;41:S245-251. 
56. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, et al. Intensity of continuous 
renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627-1638. 
57. Jalan R, Pavesi M, Saliba F, Amoros A, Fernandez J, Holland-Fischer P, Sawhney R, et al. The 
CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic 
patients without acute-on-chronic liver failure. J Hepatol 2015;62:831-840. 
58. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-chronic 
liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. 
Gastroenterology 2013;144:1426-1437, 1437. 
59. LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in 
septic shock. Crit Care Med 2000;28:2729-2732. 
60. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, et al. Consensus 
on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care 
Medicine. Intensive Care Med 2014;40:1795-1815. 
61. Rhodes A, Cusack RJ, Newman PJ, Grounds RM, Bennett ED. A randomised, controlled trial of the 
pulmonary artery catheter in critically ill patients. Intensive Care Med 2002;28:256-264. 
62. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, 
Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, et al. Comparison of two fluid-
management strategies in acute lung injury. N Engl J Med 2006;354:2564-2575. 
	 34 
63. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen 
MS, et al. Effects of intravenous fluid restriction on postoperative complications: comparison of two 
perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003;238:641-648. 
64. Rosenberg AL, Dechert RE, Park PK, Bartlett RH. Review of a large clinical series: association of 
cumulative fluid balance on outcome in acute lung injury: a retrospective review of the ARDSnet tidal 
volume study cohort. J Intensive Care Med 2009;24:35-46. 
65. Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved survival in ARDS patients 
associated with a reduction in pulmonary capillary wedge pressure. Chest 1990;97:1176-1180. 
66. Aspesi M, Gamberoni C, Severgnini P, Colombo G, Chiumello D, Minoja G, Tulli G, et al. The 
abdominal compartment syndrome. Clinical relevance. Minerva Anestesiol 2002;68:138-146. 
67. Sakka SG, Reinhart K, Meier-Hellmann A. Comparison of pulmonary artery and arterial 
thermodilution cardiac output in critically ill patients. Intensive Care Med 1999;25:843-846. 
68. Monnet X, Teboul JL. Assessment of volume responsiveness during mechanical ventilation: recent 
advances. Crit Care 2013;17:217. 
69. Biancofiore G, Critchley LA, Lee A, Yang XX, Bindi LM, Esposito M, Bisa M, et al. Evaluation of a 
new software version of the FloTrac/Vigileo (version 3.02) and a comparison with previous data in cirrhotic 
patients undergoing liver transplant surgery. Anesth Analg 2011;113:515-522. 
70. McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by 
echocardiography: a systematic review of 3 methods. Am Heart J 2003;146:388-397. 
71. Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B. Acid-base 
disturbances in critically ill patients with cirrhosis. Liver Int 2007;27:901-909. 
72. Galbois A, Bige N, Pichereau C, Boelle PY, Baudel JL, Bourcier S, Maury E, et al. Exploration of 
skin perfusion in cirrhotic patients with septic shock. J Hepatol 2015;62:549-555. 
73. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline 
for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-2256. 
74. Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med 2013;369:1243-1251. 
75. Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and 
cirrhosis. J Hepatol 2014;61:396-407. 
	 35 
76. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, et al. 
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a 
prospective, nonrandomized study. Hepatology 2002;36:941-948. 
77. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, et al. Effect of 
intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial 
peritonitis. N Engl J Med 1999;341:403-409. 
78. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, et al. 
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by 
paracentesis. Gastroenterology 1996;111:1002-1010. 
79. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, Dadamessi I, et al. 
Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a 
synthetic colloid: a randomised controlled pilot trail. Liver Int 2006;26:46-54. 
80. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, Rodriguez J, et al. Randomized 
trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in 
cirrhotic patients with ascites. Hepatology 2003;37:1147-1153. 
81. Guevara M, Terra C, Nazar A, Sola E, Fernandez J, Pavesi M, Arroyo V, et al. Albumin for bacterial 
infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J 
Hepatol 2012;57:759-765. 
82. Thevenot T, Bureau C, Oberti F, Anty R, Louvet A, Plessier A, Rudler M, et al. Effect of albumin in 
cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 
2015;62:822-830. 
83. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of 
hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 
2001;357:911-916. 
84. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, et al. 
Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-134. 
85. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, et al. 
Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-789. 
	 36 
86. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 
2002;359:1209-1210. 
87. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, et al. Effects of 
terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. 
Intensive Care Med 2004;30:597-604. 
88. Delmas A, Leone M, Rousseau S, Albanese J, Martin C. Clinical review: Vasopressin and 
terlipressin in septic shock patients. Crit Care 2005;9:212-222. 
89. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-
resistant septic shock patients. Shock 2004;22:314-319. 
90. Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, Thomas M, et al. 
Adrenocortical dysfunction in liver disease: a systematic review. Hepatology 2012;55:1282-1291. 
91. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic 
dysfunction. Hepatology 2002;36:395-402. 
92. Marik PE, Gayowski T, Starzl TE, Hepatic Cortisol R, Adrenal Pathophysiology Study G. The 
hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005;33:1254-
1259. 
93. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, et al. Adrenal insufficiency in 
patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006;43:673-681. 
94. Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Knawy BA, et al. 
Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ 
2010;182:1971-1977. 
95. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, et al. Adrenal 
insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. 
Hepatology 2006;44:1288-1295. 
96. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in 
hypotensive liver failure. Liver Int 2003;23:71-77. 
	 37 
97. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, et al. Effect 
of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. 
JAMA 2002;288:862-871. 
98. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, et al. Alterations of the human gut microbiome 
in liver cirrhosis. Nature 2014;513:59-64. 
99. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of 
small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor 
alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211. 
100. Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, et al. 
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58:949-955. 
101. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, Bach J, et al. 
Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005;42:195-
201. 
102. Rolas L, Makhezer N, Hadjoudj S, El-Benna J, Djerdjouri B, Elkrief L, Moreau R, et al. Inhibition of 
mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated 
patients with cirrhosis. Hepatology 2013;57:1163-1171. 
103. O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, et al. 
Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 
2014;20:518-523. 
104. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, et al. Second 
infections independently increase mortality in hospitalized patients with cirrhosis: the North American 
consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 2012;56:2328-
2335. 
105. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V 
consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 
2010;53:762-768. 
	 38 
106. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, 
Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal 
bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011;34:509-518. 
107. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy VG. Systemic antibiotic prophylaxis 
after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996;24:802-
806. 
108. Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, Sainz S, et al. Norfloxacin 
prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992;103:1267-
1272. 
109. Wu CK, Wang JH, Lee CH, Wu KL, Tai WC, Lu SN, Hu TH, et al. The outcome of prophylactic 
intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after 
endoscopic interventions for acute variceal hemorrhage. PLoS One 2013;8:e61666. 
110. Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary 
prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009;7:487-493. 
111. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, et al. Continuous versus inpatient 
prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 
1997;25:532-536. 
112. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, et al. Primary 
prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in 
cirrhosis. Gastroenterology 2007;133:818-824. 
113. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, et al. Norfloxacin primary 
prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J 
Hepatol 1998;29:430-436. 
114. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, Landeira C, et al. Ciprofloxacin in 
primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 
2008;48:774-779. 
	 39 
115. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the 
prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled 
trial. Eur J Gastroenterol Hepatol 2012;24:831-839. 
116. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, et al. Targeted 
versus universal decolonization to prevent ICU infection. N Engl J Med 2013;368:2255-2265. 
117. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, et al. Diagnosis, 
prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical 
Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-663. 
118. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad, II, et al. Clinical practice 
guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by 
the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45. 
119. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012;56 Suppl 
1:S1-12. 
120. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 
2009;50:2022-2033. 
121. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, et al. Altered 
profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60:940-
947. 
122. Arabi YM, Dara SI, Memish Z, Al Abdulkareem A, Tamim HM, Al-Shirawi N, Parrillo JE, et al. 
Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. 
Hepatology 2012;56:2305-2315. 
123. Patel R. MALDI-TOF MS for the Diagnosis of Infectious Diseases. Clin Chem 2015;61:100-111. 
124. Lau A, Chen S, Sleiman S, Sorrell T. Current status and future perspectives on molecular and 
serological methods in diagnostic mycology. Future Microbiol 2009;4:1185-1222. 
125. Panasiuk A, Wysocka J, Maciorkowska E, Panasiuk B, Prokopowicz D, Zak J, Radomski K. 
Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J 
Gastroenterol 2005;11:7661-7665. 
	 40 
126. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol 
2007;41:403-411. 
127. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E. 
Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, 
autopsy study. Intensive Care Med 2009;35:1526-1531. 
128. Tuon FF, Amato VS, Penteado Filho SR. Bladder irrigation with amphotericin B and fungal urinary 
tract infection--systematic review with meta-analysis. Int J Infect Dis 2009;13:701-706. 
129. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr., Filler SG, et 
al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases 
Society of America. Clin Infect Dis 2009;48:503-535. 
130. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, et al. 
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult 
patients. Clin Microbiol Infect 2012;18 Suppl 7:19-37. 
131. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and 
immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microbiol Infect Dis 
2007;26:377-384. 
132. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, Colombo M, et al. 
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 
2009;137:2105-2111. 
133. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, et al. 
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current 
management. Hepatology 2006;44:1039-1046. 
134. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008;15:473-480. 
135. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of 
thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. 
Hepatology 2003;38:230-237. 
136. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection 
in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002;37:463-470. 
	 41 
137. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 
1999;94:2569-2574. 
138. Lisman T, Van Leeuwen Y, Adelmeijer J, Pereboom ITA, Haagsma EB, Van Den Berg AP, Porte 
RJ. Interlaboratory variability in assessment of the model of end-stage liver disease score. In: Liver 
International; 2008. p. 1344-1351. 
139. Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A, Mannucci PM. 
Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: 
considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012;7:139-144. 
140. Youssef W. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver 
disease: a dual phase study. In: Am J Gastroenterol; 2003. p. 1391-1394. 
141. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. Gut 
1974;15:99-101. 
142. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, et al. 
Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440-445. 
143. Tripodi A, Primignani M, Chantarangkul V, Lemma L, Jovani M, Rebulla P, Mannucci PM. Global 
hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int 
2013;33:362-367. 
144. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, et al. 
Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21. 
145. Yang YY, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, Chang FY, et al. Plasma erythropoietin 
level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J 
Gastroenterol Hepatol 2003;18:1156-1161. 
146. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin 
increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, 
double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004;20:437-443. 
147. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW. 
Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis 
tests. J Thromb Haemost 2012;10:2116-2122. 
	 42 
148. Girdauskas E, Kempfert J, Kuntze T, Borger MA, Enders J, Fassl J, Falk V, et al. 
Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a 
prospective, randomized trial. J Thorac Cardiovasc Surg 2010;140:1117-1124. 
149. Krzanicki D, Sugavanam A, Mallett S. Intraoperative hypercoagulability during liver transplantation 
as demonstrated by thromboelastography. Liver Transpl 2013;19:852-861. 
150. Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, Burroughs A. Hypercoagulability in 
patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. 
J Hepatol 1997;26:554-559. 
151. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and 
pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008;53:3012-3017. 
152. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized 
patients in a nationwide US study. Clin Gastroenterol Hepatol 2010;8:800-805. 
153. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, et al. 
Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and 
anticoagulation. Gut 2005;54:691-697. 
154. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents 
portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 
2012;143:1253-1260 e1251-1254. 
155. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver 
transplant survival benefit. Liver Transpl 2010;16:999-1005. 
156. Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for 
perioperative management. Transfus Med Rev 2014;28:107-113. 
157. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, et al. 
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced 
cirrhosis. J Thromb Haemost 2012;10:1823-1829. 
158. Castellote J, Xiol X, Cortes-Beut R, Tremosa G, Rodriguez E, Vazquez S. Complications of 
thoracentesis in cirrhotic patients with pleural effusion. Rev Esp Enferm Dig 2001;93:566-575. 
	 43 
159. West J, Card TR. Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies. 
Gastroenterology 2010;139:1230-1237. 
160. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, et al. 
Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease 
in the HALT-C Trial. Clinical Gastroenterology and Hepatology 2010;8:877-883. 
161. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, et al. 
Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic 
review. J Hepatol 2007;47:284-294. 
162. Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality 
after extended hepatectomy for hepatocellular carcinoma. Br J Surg 2003;90:33-41. 
163. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth 2014;113:922-934. 
164. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of 
critical levels and replacement therapy. Transfusion 2014;54:1389-1405; quiz 1388. 
165. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, et al. 
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit 
Care 2013;17:R76. 
166. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, Phillips B, et al. Grading 
quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An 
overview of the GRADE approach and grading quality of evidence about interventions. Allergy 
2009;64:669-677. 
167. Arshad F, Ickx B, van Beem RT, Polak W, Grune F, Nevens F, Ilmakunnas M, et al. Prothrombin 
complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. 
BMC Surg 2013;13:22. 
168. Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated 
prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth 2013;110:764-
772. 
	 44 
169. Schochl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, et al. 
Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus 
standard fresh frozen plasma-based therapy. Crit Care 2011;15:R83. 
170. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, et 
al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 
2007;357:2227-2236. 
171. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, et al. Eltrombopag 
before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367:716-724. 
172. Moussa MM, Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic 
hepatitis C and liver cirrhosis. J Gastroenterol Hepatol 2013;28:335-341. 
173. Moulis G, Bagheri H, Sailler L, Jonville-Bera AP, Weber E, Guy C, Petitpain N, et al. Are adverse 
drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French 
PharmacoVigilance assessment. Eur J Intern Med 2014;25:777-780. 
174. Hendriks HG, van der Meer J, Klompmaker IJ, Choudhury N, Hagenaars JA, Porte RJ, de Kam PJ, 
et al. Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and 
the effects of autotransfusion of cell saver blood in 164 consecutive patients. Blood Coagul Fibrinolysis 
2000;11 Suppl 1:S87-93. 
175. Findlay JY, Rettke SR, Ereth MH, Plevak DJ, Krom RA, Kufner RP. Aprotinin reduces red blood 
cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver 
Transpl 2001;7:802-807. 
176. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, et al. A 
comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-
2331. 
177. Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients 
with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006;23:115-120. 
178. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--
definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World 
Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721. 
	 45 
179. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, Angeli P, et al. 
Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with 
and without acute-on-chronic liver failure (ACLF). J Hepatol 2014;60:275-281. 
180. Romero-Gomez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute 
decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol 2015;62:437-447. 
181. Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, Ubiali E, et al. 
Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 
2009;29:789-796. 
182. Gronbaek H, Johnsen SP, Jepsen P, Gislum M, Vilstrup H, Tage-Jensen U, Sorensen HT. Liver 
cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish 
population-based case-control study. BMC Gastroenterol 2008;8:16. 
183. Ortiz M, Cordoba J, Doval E, Jacas C, Pujadas F, Esteban R, Guardia J. Development of a clinical 
hepatic encephalopathy staging scale. Aliment Pharmacol Ther 2007;26:859-867. 
184. Hassanein T, Blei AT, Perry W, Hilsabeck R, Stange J, Larsen FS, Brown RS, Jr., et al. 
Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and 
severe hepatic encephalopathy. Am J Gastroenterol 2009;104:1392-1400. 
185. Salam M, Matherly S, Farooq IS, Stravitz RT, Sterling RK, Sanyal AJ, Gibson DP, et al. Modified-
orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther 2012;35:913-920. 
186. Inouye SK, Kosar CM, Tommet D, Schmitt EM, Puelle MR, Saczynski JS, Marcantonio ER, et al. 
The CAM-S: development and validation of a new scoring system for delirium severity in 2 cohorts. Ann 
Intern Med 2014;160:526-533. 
187. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY, et al. 
Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic 
Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 
2011;33:739-747. 
188. Jennett B, Teasdale G, Braakman R, Minderhoud J, Knill-Jones R. Predicting outcome in individual 
patients after severe head injury. Lancet 1976;1:1031-1034. 
	 46 
189. Vilstrup H, Gluud C, Hardt F, Kristensen M, Kohler O, Melgaard B, Dejgaard A, et al. Branched 
chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 
patients with cirrhosis. J Hepatol 1990;10:291-296. 
190. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with 
decompensated cirrhosis. Am J Gastroenterol 2012;107:247-252. 
191. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: 
an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-891. 
192. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, et al. Rifaximin treatment in 
hepatic encephalopathy. N Engl J Med 2010;362:1071-1081. 
193. Dhiman RK, Agrawal S, Gupta T, Duseja A, Chawla Y. Chronic Liver Failure-Sequential Organ 
Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining 
acute-on-chronic liver failure and predicting outcome. World J Gastroenterol 2014;20:14934-14941. 
194. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 
2005;365:431-433. 
195. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic 
encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010;31:1012-1017. 
196. Maharshi S, Sharma BC, Srivastava S, Jindal A. Randomised controlled trial of lactulose versus 
rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed. Gut 2015;64:1341-
1342. 
197. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute 
variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 
2011;26:996-1003. 
198. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L, Gil S, et al. Acidifying enemas 
(lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a 
double-blind, randomized clinical trial. Hepatology 1987;7:639-643. 
199. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350--electrolyte 
solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern 
Med 2014;174:1727-1733. 
	 47 
200. Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 
2013;28:307-312. 
201. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, et al. Comparison of 
rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-
blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58. 
202. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, 
controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic 
encephalopathy. Am J Gastroenterol 2013;108:1458-1463. 
203. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin 
but not colloid. Clin Sci (Lond) 2004;106:467-474. 
204. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R. 
Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled 
study. Liver Transpl 2004;10:1109-1119. 
205. Hassanein TI, Tofteng F, Brown RS, Jr., McGuire B, Lynch P, Mehta R, Larsen FS, et al. 
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced 
cirrhosis. Hepatology 2007;46:1853-1862. 
206. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F, et al. Extracorporeal 
albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the 
RELIEF trial. Hepatology 2013;57:1153-1162. 
207. Pares A, Deulofeu R, Cisneros L, Escorsell A, Salmeron JM, Caballeria J, Mas A. Albumin dialysis 
improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with 
alcoholic hepatitis and severe liver failure. Crit Care 2009;13:R8. 
208. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, et al. Albumin dialysis 
in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-
958. 
209. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of 
hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, 
controlled clinical trial. Liver Transpl 2000;6:277-286. 
	 48 
210. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with 
molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 
2003;38:24-31. 
211. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R, Hendricks R, et al. Oral L-
ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-
blind study. J Hepatol 1998;28:856-864. 
212. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C, et al. Early goal-
directed sedation versus standard sedation in mechanically ventilated critically ill patients: a pilot study*. 
Crit Care Med 2013;41:1983-1991. 
213. Goodwin HE, Gill RS, Murakami PN, Thompson CB, Lewin JJ, 3rd, Mirski MA. Dexmedetomidine 
preserves attention/calculation when used for cooperative and short-term intensive care unit sedation. J 
Crit Care 2013;28:1113  
214. Pasin L, Greco T, Feltracco P, Vittorio A, Neto CN, Cabrini L, Landoni G, et al. Dexmedetomidine 
as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials. PLoS One 
2013;8:e82913. 
215. Muzyk AJ, Kerns S, Brudney S, Gagliardi JP. Dexmedetomidine for the treatment of alcohol 
withdrawal syndrome: rationale and current status of research. CNS Drugs 2013;27:913-920. 
216. Erdman MJ, Doepker BA, Gerlach AT, Phillips GS, Elijovich L, Jones GM. A comparison of severe 
hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care 
patients. Crit Care Med 2014;42:1696-1702. 
217. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical 









Score = 1 Score = 2 Score = 3 
Liver, bilirubin (mg/dl) 
 
< 6 6 - ≤ 12 > 12 
Kidney, creatinine (mg/dl) 
 
< 2 2 - < 3.5 ≥ 3.5 or renal 
replacement therapy 
Brain, grade (West-Haven) 
 
0 1 - 2 3 - 4 
Coagulation, INR 
 
< 2 2 - < 2.5 ≥ 2.5 
Circulation, MAP (mmHg) 
 
≥ 70 < 70 Vasopressors 
Respiratory PaO2 / FiO2 
or 





≤ 300 and > 200 
 





MAP: mean arterial pressure; FiO2: fraction of inspired oxygen; PaO2: partial pressure of arterial oxygen; 
SpO2: pulse oximetric saturation 
 
